By Chris Wack BioLineRx said Monday that the Food and Drug Administration has approved Aphexda motixafortide in combination with filgrastim to mobilize stem cells to treat patients with multiple myeloma. The stock was halted at $2.18 in premarket trading. BioLineRx expects to make Aphexda... read full story